BioNTech SE (BNTX) Intangibles (2018 - 2025)
BioNTech SE (BNTX) posted Intangibles of $1.9 billion for Q4 2025, up 15.06% sequentially from $1.6 billion in Q3 2025, and up 121.34% YoY from $844.6 million in Q4 2024.
BioNTech SE (BNTX) Intangibles (2018 - 2025) Analysis & Trends
BioNTech SE has reported Intangibles for 8 years, with the latest figure at $1.9 billion in Q4 2025.
- Quarterly Intangibles rose 121.34% year-over-year to $1.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 billion (up 121.34% YoY) and the FY2025 annual result came in at $1.8 billion, up 114.83% from the prior year.
- Intangibles grew to $1.9 billion in Q4 2025 per BNTX's latest filing, from $1.6 billion in the prior quarter.
- Over five years, Intangibles peaked at $1.9 billion in Q4 2025 and troughed at $192.1 million in Q3 2021.
- A 5-year average of $741.2 million and a median of $635.2 million in 2023 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2024: Intangibles soared 312.61% in 2023, then fell 14.77% in 2024.
- Over 5 years, Intangibles stood at $228.1 million in 2021, then increased by 5.29% to $240.2 million in 2022, then jumped by 312.61% to $990.9 million in 2023, then dropped by 14.77% to $844.6 million in 2024, then soared by 121.34% to $1.9 billion in 2025.
- According to Business Quant data, Intangibles over the past three periods registered $1.9 billion, $1.6 billion, and $1.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 1.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.87 Bn |
| Sep 30, 2025 | 1.62 Bn |
| Jun 30, 2025 | 1.68 Bn |
| Mar 31, 2025 | 1.59 Bn |
| Dec 31, 2024 | 844.62 Mn |
| Sep 30, 2024 | 959.73 Mn |
| Jun 30, 2024 | 928.60 Mn |
| Mar 31, 2024 | 892.66 Mn |
| Dec 31, 2023 | 865.16 Mn |
| Sep 30, 2023 | 724.46 Mn |
| Jun 30, 2023 | 545.99 Mn |
| Mar 31, 2023 | 406.37 Mn |
| Dec 31, 2022 | 240.17 Mn |
| Sep 30, 2022 | 228.07 Mn |
| Jun 30, 2022 | 236.25 Mn |
| Mar 31, 2022 | 242.42 Mn |
| Dec 31, 2021 | 228.11 Mn |
| Sep 30, 2021 | 192.11 Mn |
| Jun 30, 2021 | 197.62 Mn |
| Mar 31, 2021 | 199.27 Mn |